Dynavax Technologies Corporation's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the third quarter 2025 to a ratio of 5.29, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the third quarter 2025. Average receivable collection period, for the Dynavax Technologies in Sep 30 2025 quarter, has decreased to 69 days, compared to 73 days, in the Jun 30 2025 quarter.

If we take a look into Healthcare sector 355 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Sep 30 2025 from 2319 to 2586.

What is Receivable Turnover Ratio?
What is Dynavax Technologies Corporation Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

DVAX Receivables Turnover Ratio	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter
Y / Y Receivable Change	-2.6 %	17.11 %	22.54 %	5.33 %	60.62 %
Y / Y Revenue Change	17.67 %	29.33 %	34.21 %	29.56 %	17.68 %
Receivable Turnover Ratio (TTM)	5.29	5.02	4.88	4.8	4.56
DVAX's Total Ranking	# 2586	# 2319	# 2530	# 2596	# 2715
Accounts Receivable average collection period days	69	73	75	76	80
Seq. Receivable Change	-0.03 %	29.68 %	20.58 %	-37.69 %	20.19 %
Seq. Revenue Change	-0.59 %	40.02 %	-5.37 %	-10.66 %	9.26 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 107
Healthcare Sector	# 356
Overall Market	# 2586

Receivable Turnover Ratio Statistics
High	Average	Low
9.86	4.81	0.33
(Dec 31 2014)		(Dec 31 2017)

DVAX Company Profile • Back to DVAX Efficiency Comparisons • Compare DVAX Receivables Turnover Ratio to its Competitors

Financial Statements
Dynavax Technologies's Accounts Receivable	$ 73 Millions	Visit DVAX's Balance sheet
Dynavax Technologies's Sales TTM	$ 331 Millions	Visit DVAX's Income Statement
Sources of DVAX's Revenues		Visit DVAX's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
DVAX's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
DVAX's Growth Rates	DVAX's Roa	DVAX's Inventory Turnover Ratio	DVAX's Dividend Comparisons
DVAX's Profitability Ratios	DVAX's Roi	DVAX's Asset Turnover Ratio	DVAX's Dividend Growth
DVAX's Valuation Ratios	DVAX's Roe	DVAX's Financial Strength Ratios	DVAX's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2025, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Sep 30 2025	Receivable at quarter ending Sep 30 2025
Sutro Biopharma Inc	12.39	$ 105.646 Millions	$ 8.525 Millions
Newamsterdam Pharma Company N v	12.34	$ 35.243 Millions	$ 2.856 Millions
Escalon Medical Corp	12.32	$ 11.940 Millions	$ 0.969 Millions
Scorpius Holdings inc	12.30	$ 1.716 Millions	$ 0.140 Millions
Harvard Apparatus Regenerative Technology Inc	12.23	$ 0.743 Millions	$ 0.061 Millions
Cytokinetics Incorporated	12.08	$ 87.211 Millions	$ 7.220 Millions
Option Care Health Inc	12.01	$ 5,532.505 Millions	$ 460.534 Millions
Corcept Therapeutics Inc	11.86	$ 741.172 Millions	$ 62.498 Millions
Ss Innovations International Inc	11.86	$ 40.946 Millions	$ 3.454 Millions
Chemed Corporation	11.80	$ 2,530.634 Millions	$ 214.372 Millions
Ethema Health Corporation	11.72	$ 15.420 Millions	$ 1.315 Millions
Skinhealth Systems Inc	11.55	$ 301.672 Millions	$ 26.128 Millions
Nrc Health	11.53	$ 139.104 Millions	$ 12.066 Millions
Teladoc Health Inc	11.45	$ 2,528.199 Millions	$ 220.826 Millions
Integrated Biopharma Inc	11.16	$ 52.210 Millions	$ 4.680 Millions
Nexgel Inc	10.99	$ 9.479 Millions	$ 0.863 Millions
National Healthcare Corp	10.86	$ 1,500.618 Millions	$ 138.148 Millions
Lftd Partners Inc	10.78	$ 36.986 Millions	$ 3.430 Millions
Tandem Diabetes Care Inc	10.78	$ 1,005.832 Millions	$ 93.295 Millions
Sanuwave Health Inc	10.54	$ 41.283 Millions	$ 3.916 Millions
Dbv Technologies S a	10.51	$ 5.550 Millions	$ 0.528 Millions
Lifestance Health Group Inc	10.46	$ 1,367.570 Millions	$ 130.682 Millions
Exact Sciences Corporation	10.37	$ 3,080.353 Millions	$ 297.039 Millions
Novavax inc	10.30	$ 1,064.651 Millions	$ 103.341 Millions
Lifeloc Technologies Inc	10.20	$ 8.664 Millions	$ 0.849 Millions
Addus Homecare Corp	10.13	$ 1,346.751 Millions	$ 132.909 Millions
Sintx Technologies Inc	9.96	$ 1.270 Millions	$ 0.128 Millions
Zomedica Corp	9.94	$ 30.355 Millions	$ 3.054 Millions
Sunshine Biopharma Inc	9.92	$ 37.324 Millions	$ 3.764 Millions
Vireo Growth Inc.	9.91	$ 189.242 Millions	$ 19.086 Millions

Date modified: 2026-08-29T17:19:47+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.